News

This biologics license application (BLA) submission by Ipsen is intended to address the concerns cited by the FDA when it declined to file the Reloxin BLA in January

Deals have been brokered with three international distributors to date – Pacific Medical, which will target select countries in Asia; Sanitas covering Turkey; and the Golden Triangle Organization,

The pilot program included 100 participants (50 in the PTP group and 50 in a control group). Patients were evaluated for program participation eligibility by Community Bridges treatment

In the clinically evaluable population of the study, the clinical success rate at visit 3 (End of Therapy) for Microcyn-alone-treated patients was 77.8% compared to 61.1% for the

The test simultaneously detects and identifies cystic fibrosis (CF) mutations in patient DNA samples. The InPlex CF Molecular Test delivers the accuracy of Third Wave’s Invader chemistry in

The trial is being conducted at 30 allergy specialty centers across the US and will enroll approximately 458 patients. Participants must be ages 18-50 and have a history

Anadis and Garden State Nutritionals (GSN) plan to introduce in the coming months and years a range of products, all based on Anadis’s proprietary and all-natural milk-derived (colostrum)

The study included a four-week, multicenter, double-blind treatment period during which 433 children were randomized to receive either Nasacort AQ 110 micrograms or placebo as one spray per

Genentech has stated that it plans to initiate three Phase II clinical trials of GDC-0449 in 2008, which include a trial in metastatic colorectal cancer during the first